Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details)

v3.23.3
Net Loss per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details) - shares
 3 Months Ended 9 Months Ended
Oct. 01, 2023
Oct. 02, 2022
Oct. 01, 2023
Oct. 02, 2022
Stock options outstanding        
Subsidiary Sale Of Stock [Line Items]        
Anti-dilutive securities 3,075,138 5,083,643 3,075,138 5,083,643
Restricted stock units and performance restricted stock units outstanding        
Subsidiary Sale Of Stock [Line Items]        
Anti-dilutive securities 12,602,239 5,933,914 12,602,239 5,933,914
Assumed conversion of Convertible Senior Notes        
Subsidiary Sale Of Stock [Line Items]        
Anti-dilutive securities 11,053,800 0 6,608,868 0
Private Placement Warrants outstanding        
Subsidiary Sale Of Stock [Line Items]        
Anti-dilutive securities 0 6,000,000 0 0
Employee stock purchase plan estimated shares        
Subsidiary Sale Of Stock [Line Items]        
Anti-dilutive securities 243,474 380,847 243,474 380,847